“North America is for sure going to accelerate the growth in the human microbiome market moving forward. We at GA are very excited to fuel this growth with our GA-map® technology platform” – Genetic Analysis CEO Ronny Hermansen
The focus of the collaboration is the GA-map® Dysbiosis Test which detects and characterizes imbalance in the gut microbiota (dysbiosis) in fecal samples.
Eagle Biosciences, Inc., a North American distributor of assay kits and antibodies, recently announced a distribution agreement with Genetic Analysis AS, a Norwegian molecular diagnostics company. The focus of the collaboration is on the unique, patented GA-map® Dysbiosis Test which detects and characterizes imbalance in the gut microbiota (dysbiosis) in human fecal samples.